Biosimilars

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

With its blockbuster drug's patent cliff looming, Merck's leadership faces high stakes at the JPM conference to unveil its strategy for future growth.

Amid a crucial patent appeal and a competitive market, Scilex Holding hires renowned trial lawyer Marc Kasowitz, signaling an aggressive new legal strategy.

Ironwood Pharma forecasts a massive profit jump by lowering its top drug's price, a bold move as it advances its rare disease pipeline for future growth.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Celltrion's SteQeyma autoinjector gets a CHMP nod, enhancing patient care and intensifying competition in Europe's crowded biosimilar market.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

Biotech startup Bio Usawa appoints a world-renowned health expert to lead its access board, betting its entire business model on making advanced drugs affordable.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A new partnership aims to commercialize Arbli™, the first liquid losartan, leveraging a digital platform to solve patient adherence and capture market share.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?